AxonDx’s nCYTE™ technology scans un-enriched blood samples in minutes, finds cancer derived material, and offers morphological and outsourced molecular characterization of positive cells. The nCYTE™ approach is fast, vastly more accurate, compact, and inexpensive enough (< $100) to be offered at the point of care. Collectively, the nCYTE™ advances represent new era, game-changing improvements over all existing technologies.